FOSTER CITY, Calif.--(BUSINESS WIRE)--Dren Bio, Inc. (“Dren Bio” or the “Company”), a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS).

加利福尼亚州福斯特城——（商业新闻短讯）——Dren Bio，Inc.（“Dren Bio”或“公司”），一家私营的临床阶段生物制药公司，开发针对癌症、自身免疫和其他严重疾病的抗体治疗剂，今天宣布与诺华制药公司（Novartis AG）（纽约证券交易所：NVS）的子公司诺华制药公司（Novartis Pharma AG）进行战略合作。

The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform..

该合作将专注于使用Dren Bio专有的靶向骨髓接受者和吞噬作用平台发现和开发针对癌症的治疗性双特异性抗体。。

“Our agreement with Dren Bio is a promising opportunity to discover novel bispecific antibody therapies for cancer, building on our longstanding expertise in immuno-oncology science at Novartis,” said Shiva Malek, Ph.D., Global Head of Oncology for Biomedical Research at Novartis. “We’re excited to collaborate to bring forward new therapeutic options for patients living with cancer, complementing our strategic efforts across a wide range of modalities, including targeted therapies, biologics, radioligand therapies and CAR-Ts.”.

诺华生物医学研究肿瘤学全球负责人Shiva Malek博士说：“我们与Dren Bio的协议是一个很有希望的机会，可以利用我们在诺华长期以来在免疫肿瘤学科学方面的专业知识，发现针对癌症的新型双特异性抗体疗法。”。“我们很高兴能够合作为癌症患者提出新的治疗选择，补充我们在各种方式上的战略努力，包括靶向治疗，生物制剂，放射性配体治疗和CAR-Ts。”。

“We are thrilled to establish this new collaboration with Novartis, a global leader in oncology,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio. “Combining the proven capabilities of Novartis in oncology drug development with Dren Bio’s novel platform could enable the advancement of important new therapies for patients.”.

Dren Bio首席执行官Nenad Tomasevic博士说：“我们很高兴与全球肿瘤学领导者诺华建立这一新的合作关系。将诺华在肿瘤药物开发方面的成熟能力与Dren Bio的新型平台相结合，可以为患者提供重要的新疗法。”。

Amit Mehta, Ph.D., Chief Operating Officer and Chief Business Officer of Dren Bio, added, “Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform is designed to deplete various disease-causing agents and has led to a rich and diverse pipeline. This collaboration will benefit from Novartis’ impressive track record of developing novel medicines and help further expand the reach of our platform.”.

Dren Bio首席运营官兼首席商务官Amit Mehta博士补充道：“Dren Bio的靶向骨髓接受者和吞噬作用平台旨在消除各种致病因子，并产生了丰富多样的渠道。这种合作将受益于诺华在开发新药方面令人印象深刻的记录，并有助于进一步扩大我们平台的覆盖面。”。

Under the terms of the agreement, Dren Bio will receive a total upfront consideration of $150 million from Novartis, which includes a $25 million equity investment in the Company. Dren Bio is also eligible to receive up to $2.85 billion in additional cash payments upon achieving certain preclinical, clinical, regulatory, and commercial milestones, as well as tiered royalties on future net sales of any commercialized products resulting from the collaboration.

根据协议条款，德伦生物将从诺华获得1.5亿美元的前期对价，其中包括对该公司2500万美元的股权投资。在实现某些临床前，临床，监管和商业里程碑后，Dren Bio还有资格获得高达28.5亿美元的额外现金支付，以及合作产生的任何商业化产品未来净销售额的分层版税。

Dren Bio and Novartis will collaborate to advance selected targeted myeloid engager programs in oncology through clinical candidate selection, at which point Novartis will assume full responsibility for all remaining development, manufacturing, regulatory, and commercialization activities..

Dren Bio和诺华将通过临床候选人选择合作推进选定的肿瘤学靶向骨髓参与者计划，届时诺华将对所有剩余的开发、制造、监管和商业化活动承担全部责任。。

About Dren Bio

关于德润生物

Dren Bio is a privately held, clinical-stage biopharmaceutical company pioneering the discovery and development of novel first-in-class antibody therapeutics for the treatment of cancer, autoimmune, and other serious diseases. The Company’s lead product candidate, DR-01, is a first-in-class antibody therapeutic capable of selectively depleting terminally differentiated cytotoxic cells such as autoreactive CD8 T cells, which are known to play a pathogenic role in various cancer and autoimmune diseases.

Dren Bio是一家私营的临床阶段生物制药公司，率先发现和开发用于治疗癌症，自身免疫和其他严重疾病的新型一流抗体疗法。该公司的主要候选产品DR-01是一流的抗体治疗剂，能够选择性地消耗终末分化的细胞毒性细胞，例如已知在各种癌症和自身免疫性疾病中起致病作用的自身反应性CD8 T细胞。

DR-01 is currently being evaluated in a Phase 2 study in patients with cytotoxic lymphomas and is expanding into various autoimmune indications. In addition to DR-01, Dren Bio’s Targeted Myeloid Engager and Phagocytosis Platform is a bispecific antibody-based technology that induces potent depletion of pathogenic cells, protein aggregates, and other disease-causing agents by engaging a novel phagocytic receptor that is selectively expressed on myeloid cells.

DR-01目前正在细胞毒性淋巴瘤患者的2期研究中进行评估，并正在扩展到各种自身免疫适应症。除DR-01外，Dren Bio的靶向骨髓接受者和吞噬作用平台是一种基于双特异性抗体的技术，通过参与选择性表达的新型吞噬受体，诱导致病细胞，蛋白质聚集体和其他致病因子的有效消耗。骨髓细胞。

Bispecific antibodies generated from the platform are specifically engineered to enable controlled myeloid cell activation only in the presence of the target antigen, which may result in greater therapeutic indexes and offer superior safety profiles compared to other therapeutic modalities such as T-cell engagers and Antibody Drug Conjugates (ADCs).

从平台产生的双特异性抗体经过专门设计，仅在靶抗原存在下才能实现受控的骨髓细胞活化，与其他治疗方式（如T细胞接受者和抗体-药物缀合物）相比，这可能导致更大的治疗指数并提供更优的安全性（ADC）。

The Company’s lead platform program, DR-0201, is capable of engaging both tissue-resident and trafficking myeloid cells to induce deep B cell depletion via targeted phagocytosis. DR-0201 has demonstrated a favorable preclinical safety profile in multiple non-human primate studies with no cytokine release syndrome or neurotoxicity observed and is currently being evaluated in a Phase 1 study in B-NHL patients.

该公司的领先平台计划DR-0201能够通过靶向吞噬作用使组织驻留和运输骨髓细胞诱导深度B细胞耗竭。DR-0201在多项非人灵长类动物研究中表现出良好的临床前安全性，未观察到细胞因子释放综合征或神经毒性，目前正在B-NHL患者的1期研究中进行评估。

Collectively, Dren Bio’s two distinct clinical programs represent .

总的来说，Dren Bio的两个不同的临床项目代表了。